Wanbury Ltd 05 Nov 2026 12:00 AM
Wanbury Ltd consolidated sales up 12.09% on year in Q3FY2026,
Wanbury Ltd share price declined by 0.05% to Rs 192.55 after the company`s net profit tanked by 36.77% to Rs 8.53 crore, while revenue from operations edged up 12.09% to Rs 182.91 crore in Q3FY26 over Q2FY25. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.14%. It has inched up 2.03% over last one week and ticked higher by 1.77% in last one month while the market capitalization of Wanbury Ltd has improved by 6.65% and 24.39% in the same period respectively. Profit before tax (PBT) of Wanbury Ltd stood at Rs 12.36 crore in Q3 FY26, rallying 51.29% year-on-year, and slipping 9.18% quarter-on-quarter. EBITDA came in at Rs 23 crore, expanding by 23.08% YoY and declining 6.14% sequentially. Total expenses went up by 15.44% to Rs 164.37 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 87.88 crore, witnessing a sharp rise of 20.75% YoY, while employee benefits expense was at Rs 34.47 crore, surging 20.15% YoY. For the TTM ended FY26, revenue from operations inched higher 4.14% to Rs 599.51 crore, while net profit witnessed a sharp fall of 45.44% to Rs 30.53 crore, compared to previous TTM. EBITDA surged by 6629% to Rs 72.83 crore, and PBT collapsed by 47.55% to Rs 29.55 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 26.1 crore in FY26, as against Rs 4.66 crore in FY25. Wanbury Ltd crashed 27.84% in last one year, underperforming the benchmark BSE Sensex which has softened by 7.38% during the same period.
Wanbury Ltd 28 Oct 2026 12:00 AM
Wanbury Limited to convene a board meeting November 4 to review financial results,
Wanbury Limited will hold a board meeting on Wednesday, November 04, 2026, to consider and approve the unaudited financial results (standalone & consolidated) for the second quarter and half year ended September 30, 2026, according to a regulatory filing. Trading in the company`s securities will be closed for directors, officers, key managerial personnel, and designated employees until 48 hours after the financial results are declared.
Wanbury Ltd 04 Aug 2026 12:00 AM
Wanbury to hold board meeting,
Wanbury will hold a meeting of the Board of Directors of the Company on 11 August 2026.
Wanbury Ltd 30 Jul 2026 12:00 AM
Wanbury update on filing of DFM in US and South Korea,
Wanbury recently received �No DMF deficiency letter� from the office of USFDA (US Food and Drug Administration) for multiple ANDAs (Abbreviated New Drug Applications) with Metformin HCl API source of Wanbury for different formulations. Further, Wanbury expanded business opportunities in South Korea for one more API by filing the DMF. Wanbury is committed for supply of best APIs to the new market for well-being of human being.
Wanbury Ltd 21 Jul 2026 12:00 AM
USFDA concludes inspection of Wanbury`s facility at Tanuku, Andhra Pradesh,
Wanbury announced that a routine current Good Manufacturing Practices ( cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company`s facility at Tanuku, West Godavari District, Andhra Pradesh during the period from 13 July 2026 to 17 July 2026. At the conclusion of the inspection, the U.S.FDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time.
Subscribe for our
newsletter
Open Account Now